Rare lephants
Screener

Labcorp Holdings Inc.

LH ·Healthcare, Medical Care Facilities, United States
Analysis › Moat Score

Moat Score — Labcorp Holdings Inc.

Total Moat Score 12 / 30
Moat Factor Score Analysis
Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. 2 / 5 Decades of laboratory accreditations and regulatory approvals create some barrier to entry, but routine diagnostic testing itself carries little differentiated intellectual property.
Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. 3 / 5 A national network of roughly 2,000 patient service centers and high testing volume give Labcorp real cost-per-test advantages over smaller or regional labs.
Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. 1 / 5 Reimbursement rates are set and continually pressured downward by government and private payers, leaving Labcorp with little ability to raise prices on its high-volume, commoditized routine tests.
Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. 0 / 5 A logistics- and scale-driven testing business with no direct network effect between patients or providers.
Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. 3 / 5 Sticky institutional relationships — insurer contracts, health-system integrations, and biopharma clinical-trial partnerships — create real switching costs beyond what an individual patient experiences.
Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. 3 / 5 The national specimen-collection and logistics network is expensive and slow to replicate, and the market is effectively a duopoly with Quest Diagnostics, limiting room for new large-scale entrants.